Illumina’s multibillion-dollar quest for Grail—high-reaching, yet ultimately doomed—is nearing its conclusion. The DNA ...

The FDA’s “Operation Warp Speed” equivalent for rare disease will include programs from Denali Therapeutics, Neurogene, Larimar Therapeutics and Grace Science, the companies announced June 3 in ...

Viking Therapeutics is pulling up some extra long boats full of reasons the metabolic dysfunction-associated steatohepatitis (MASH) drug VK2809 could be a winner, but executives were mum on exactly ...

Merck KGaA is hoping to sprout some new oncology and immunology therapeutics with Biolojic Design’s AI-driven drug discovery engine. | Merck KGaA is hoping to sprout some new oncology and immunology ...

Though immunotherapies have made strong inroads in the fight against cancer, knowing which drugs will work the best in which patients—and with the first dose—has remained a challenge. Researchers at ...

Annexon’s monoclonal antibody ANX005 reduced disability in patients with the rare autoimmune disorder Guillain-Barré syndrome (GBS), meeting the main goal of a phase 3 trial. | Annexon’s monoclonal ...

A clinical research company has pleaded guilty and agreed to pay a record $35 million fine to resolve an animal welfare case that involved the seizure of more than 4,000 beagles in 2022. | A clinical ...

A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. | A new trend has emerged at this ...

Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

The Australian and New Zealand life sciences sector will get a nice boost from a new A$270 million ($180 million) fund from venture capital firm Brandon Capital. Money from the Brandon Capital Fund VI ...

Hypertrophic cardiomyopathy, or HCM, is a common but potentially lethal heart disease. | While researchers have tried for decades to understand the contribution of the many genes linked to HCM, ...

BridgeBio reported top-line data from the midphase PROPEL 2 trial in March 2023 and followed up with six-month data around one year ago. Tuesday, the biotech unwrapped 12- and 18-month data that add ...